# A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors

> **NCT00634231** · PHASE1 · COMPLETED · sponsor: **Candel Therapeutics, Inc.** · enrollment: 8 (actual)

## Conditions studied

- Malignant Glioma
- Recurrent Ependymoma

## Interventions

- **BIOLOGICAL:** AdV-tk
- **DRUG:** valacyclovir
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT00634231
- **Lead sponsor:** Candel Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2015-12
- **Final completion:** 2021-06
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2023-08-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00634231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00634231, "A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00634231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*